Detecting Cancer in Routine Blood Work
Detecting cancer in routine blood work may not have been possible before, but scientists have made major strides. A new blood test, known as Galleri, can detect more than 45 types of cancer without recommended screening.
Importance of Early Cancer Detection
Early detection of cancer plays a crucial role in determining the outcome of treatment. The earlier cancer is identified, the more likely it is to be treatable, curable, or even asymptomatic. This is particularly important given the often silent nature of many cancers in their early stages, where they may not produce noticeable symptoms. Early detection can save lives by enabling timely intervention before the cancer progresses to a more advanced, less manageable stage.
One of the individuals benefiting from early cancer detection is Rosemary Jemo, a 75-year-old woman who leads an active lifestyle as an exercise instructor and hairdresser. Rosemary was among the 10,000 women aged 65-75 years old enrolled in a groundbreaking study conducted by Johns Hopkins University, known as the DETECT study. These women had no previous history of cancer and were seemingly healthy. However, Rosemary's routine blood work as part of the study revealed something alarming. After additional tests, doctors discovered a football-sized tumor in one of her ovaries. Thanks to early detection, her condition was identified before it became symptomatic, highlighting the critical role of regular screenings.
Advancements in Routine Blood Work for Cancer Detection
Historically, routine blood work was not designed to detect cancer, especially in patients without symptoms. However, significant advancements in medical science are changing this landscape. One of the most promising developments is the introduction of a new blood test known as Galleri, which has the potential to revolutionize cancer screening. Galleri can detect more than 45 different types of cancer, including those for which there are no recommended screening protocols.
This innovative blood test offers hope for reducing the human toll of cancer by catching the disease in its early stages. Currently available in some U.S. health systems, Galleri marks the beginning of a new era in cancer prevention and screening. It could lead to a future where routine blood tests are a common method of detecting cancer, making it easier to catch and treat the disease before it becomes life-threatening.
How Routine Blood Tests Can Identify Cancer
The process of detecting cancer through routine blood work involves taking a sample from a patient who may not show any symptoms of the disease. The test looks for mutated DNA or abnormal proteins produced by cancerous cells. One key marker that these cells produce is carcinoembryonic antigen (CEA), a substance often present in higher levels in the blood of cancer patients.
Although a high CEA level is not specific to any particular type of cancer, it can raise suspicions and prompt further testing. Regular monitoring of CEA levels can also help doctors determine whether a patient’s cancer is responding to treatment. If levels decrease, it may indicate that the treatment is effective. On the other hand, rising CEA levels could signal the need for a change in treatment strategy.
Detecting Cancer Biomarkers: A New Frontier
The detection of cancer biomarkers through blood tests is a promising new approach to early cancer detection. Biomarkers are substances that can indicate the presence of cancer in the body, and most cancers can be diagnosed through specific biomarker tests. Currently, screening tests exist for five types of cancer: cervical, breast, lung, colon, and prostate. However, many other cancer types lack screening tests, which often leads to late diagnoses and poorer outcomes.
According to Dr. Joshua Ofman, the Chief Medical Officer of GRAIL—a company that is pioneering the development of liquid biopsy technology—about 71% of cancer-related deaths occur because the disease is detected too late. Liquid biopsies, like Galleri, can identify cancer biomarkers in the blood at earlier stages, providing a powerful tool for catching cancers before they spread.
One common test used to detect cancer biomarkers is the complete blood count (CBC). This test measures the levels of red blood cells, white blood cells, and platelets in a person’s blood. Abnormalities in these levels can sometimes indicate the presence of cancer. For example, a significantly high or low white blood cell count could signal blood cancers like leukemia or lymphoma. By tracking these blood cell counts over time, doctors can also assess whether the cancer has spread to other parts of the body.
Flow Cytometry: A Detailed Approach to Cancer Detection
Another cutting-edge technique in cancer detection is flow cytometry. This test is designed to identify cancer cells by analyzing their DNA content, specifically looking at a characteristic known as "ploidy." In healthy cells, the DNA content follows a regular pattern that matches the cell type. However, cancerous cells often display irregular patterns, known as aneuploidy, which can make them more aggressive and more likely to spread.
Flow cytometry offers several advantages over traditional cancer tests. It is highly sensitive and can detect specific types of cancer cells by analyzing the proteins they produce on their surface. This method involves treating a blood sample with special antibodies that bind to cancer cells. When the sample is passed through a laser beam, these antibodies emit light, making it easier for doctors to identify the cancer cells.
In addition to detecting cancer, flow cytometry can help assess the risk of cancer recurrence. It allows doctors to examine blood cells under a microscope for any chromosomal changes, providing valuable information about the genetic mutations associated with certain types of cancer. This cytogenetic analysis can be particularly useful in diagnosing blood cancers, such as leukemia, and guiding treatment decisions.
The Future of Cancer Screening
The advancements in cancer detection through routine blood work, biomarker identification, and flow cytometry are paving the way for a future where cancer is caught early and treated effectively. While there is still much work to be done, the progress made so far is promising. Technologies like Galleri and liquid biopsies could soon become standard practice, significantly improving survival rates and reducing the burden of cancer on society.
As we continue to push the boundaries of medical science, the goal is to make cancer detection as routine as possible, ensuring that more people like Rosemary Jemo can benefit from early intervention and lead healthy, cancer-free lives.
